AFT COVID-19 Updates
To Access the FAQ for COVID-19 Pandemic Related Documentation and Testing, please click HERE
To Access the SDC at Mayo Notice: New COVID-19 Form for AFT Trials, please click HERE
To access AFT's COVID-19 Mitigation and Response Plan (updated 04/22/2020), please click HERE
To access the AFT Biorepository and Laboratory Closures and Limited Operations Plan, please click HERE
NOTICE: Updated BioMS web URL information HERE
To access the Mayo SDC Notice for Temporary RAVE data entry instructions for biospecimens on AFT trials, please click HERE
To access the AFT Biorepository Shipment Update due to COVID-19 Biobank Restrictions, please click HERE
Alliance Foundation Trials, LLC (AFT) is a research organization that develops and conducts cancer clinical trials, working closely with pharmaceutical partners, research collaborators and the Alliance for Clinical Trials in Oncology scientific investigators and institutional member network. AFT seeks to fulfill the vision of the Alliance for Clinical Trials in Oncology to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.
Established in 2014 as a limited liability corporation, AFT is managed by the Alliance for Clinical Trials in Oncology Foundation, which is its sole member. The AFT operational structure and funding sources are separate from the Alliance clinical trials program funded by the National Cancer Institute (NCI).
Monica M. Bertagnolli, MD | President
An internationally renowned surgeon-scientist, Monica M. Bertagnolli, MD, is Chief of the Division of Surgical Oncology at Brigham and Women's Hospital and Professor of Surgery at Harvard Medical School. She is also Group Chair of the Alliance for Clinical Trials in Oncology and President of the Alliance for Clinical Trials in Oncology Foundation. In addition, Dr. Bertagnolli is the immediate past president of ASCO and the current Chair of the Board of Directors.
Her innovative research has focused on gastrointestinal tumor biology, striving to develop patient-specific cancer prevention and treatment strategies. Dr. Bertagnolli specifically investigates the adenomatous polyposis coli (APC) gene function and its regulation of colorectal cancer. Her clinical practice is dedicated to patients with germline APC gene mutations.
Suzanne George, MD | Vice President
A leading medical oncologist and expert in sarcoma management and clinical investigation, Suzanne George, MD, is Clinical Director at the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. She is also Group Vice-Chair of the Alliance for Clinical Trials in Oncology.
Her interests have led her to develop and lead multiple clinical trials evaluating novel therapeutics for patients with advanced sarcomas and GIST, much of which has impacted the standard of care for patients with these diseases. She has also led one of the largest clinical multidisciplinary sarcoma teams, bringing together various specialists with the goal of optimizing patient care and outcomes.
Olwen Hahn, MD | Chief Scientific Officer
Olwen Hahn, MD, is Associate Professor of Medicine at the University of Chicago. As her clinical practice focuses on the diagnosis and treatment of breast cancer, she is also Principal Investigator and Director of the Central Protocol Operations Program at the Alliance for Clinical Trials in Oncology.
In addition, she serves as the primary investigator on multiple studies that examine the effectiveness of new drugs in breast cancer. She has authored numerous articles in scientific journals. Dr. Hahn has also been the recipient of the University of Chicago Distinguished Clinician Award, and is a Junior Faculty Scholar of the Bucksbaum Institute for Clinical Excellence.
- Shira Dinner, MD | Northwestern University
- David Kozono, MD, PhD | Dana-Farber Cancer Institute
- Otto Metzger, MD | Dana-Farber Cancer Institute
- Priya Kumthekar, MD | Northwestern University
- Ardaman Shergill, MD | University of Chicago
- Michael Tetzlaff, MD, PhD | MD Anderson Cancer Center
- Anna Weiss, MD | Dana-Farber Cancer Institute
NewsGet the latest from AFT
AFT offers clinical trial investigators, pharmaceutical partners and the Alliance for Clinical Trials in Oncology institutional member network collaborative opportunities to develop and conduct trials, in addition to NCI-funded initiatives. This expands access and trial design options. AFT studies are developed by the Alliance scientific committees and are integrated into scientific goals of the committees.
Sites eligible to participate in AFT trials are members of the Alliance for Clinical Trials in Oncology network in good standing. AFT determines site-protocol matches based on previous site performance, accrual reports and results from its feasibility process. AFT invites sites that meet these criteria to participate in trials.
Site Identification Criteria
- Overall good standing as Alliance member
- AFT conducts feasibility process to assess site’s capability to conduct trial based on specific protocol requirements
- AFT reviews previous site performance and accrual reports to determine site selection in general
- AFT invites site to participate
There are several differences between AFT Trials and Alliance Trials. The areas of difference are noted below.
AFT accrual credits are applied only after the network has met their requirements for Alliance Membership. Click here for more information.
Differences Between AFT and Alliance Trials
- Study Selection and Development
- Site Selection
- Operations Systems and Partners
- Contracts and Funding
- Alliance Membership Accrual
- Operations Systems and Partners